• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ClearPoint Neuro Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/23/25 4:30:10 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care
    Get the next $CLPT alert in real time by email
    8-K
    0001285550false00012855502025-05-232025-05-23

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 23, 2025

     

     

    CLEARPOINT NEURO, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-34822

    58-2394628

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    120 S. Sierra Ave., Suite 100

     

    Solana Beach, California

     

    92075

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 888 287-9109

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.01 par value per share

     

    CLPT

     

    The Nasdaq Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    The annual meeting of the stockholders of ClearPoint Neuro, Inc. (the “Company”) was held on May 21, 2025 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted to approve the adoption of the ClearPoint Neuro, Inc. Sixth Amended and Restated 2013 Incentive Compensation Plan (the “Plan”). The Company’s Board of Directors had previously adopted and approved the Plan, subject to stockholder approval. A description of the terms and conditions of the Plan is set forth in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on April 9, 2025 in connection with the Annual Meeting (the “Proxy Statement”) under “Proposal No. 6 - Approval of the Sixth Amended and Restated 2013 Incentive Compensation Plan,” and such description is incorporated herein by reference. The descriptions set forth herein and in the Proxy Statement are summaries and are qualified in their entirety by the full text of the Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    At the Annual Meeting, the Company’s stockholders considered and voted on the following proposals, which are described in more detail in the Proxy Statement:

     

    (1)

    The election of eight directors to serve until the 2026 annual meeting of stockholders;

     

     

    (2)

    The ratification of the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025;

     

     

    (3)

    The advisory approval of executive compensation;

     

     

    (4)

    The advisory vote on the frequency of future advisory votes on executive compensation;

     

     

    (5)

    The approval of the Company’s Amended and Restated 2021 Employee Stock Purchase Plan; and,

     

     

    (6)

    The approval of the Company’s Sixth Amended and Restated 2013 Incentive Compensation Plan.

     

    Each proposal was approved and the final voting results for each proposal are described below. For beneficial owners holding the Company’s common stock at a bank or broker institution, a “broker non-vote” occurred if the owner failed to give voting instructions, and the bank or broker was otherwise restricted from voting on the owner’s behalf.

    1.
    Election of Directors. The following named persons were elected as directors of the Company to serve until the 2026 annual meeting of stockholders or until their successors have been duly elected and qualified or until their earlier death, resignation, disqualification or removal. The votes were cast as follows:

    Name

    For

    Withheld

    Broker Non-Votes

    Joseph M. Burnett

    9,980,965

    72,122

    8,647,207

    R. John Fletcher

    9,408,193

    644,894

    8,647,207

    Lynnette C. Fallon

    9,909,422

    143,665

    8,647,207

    Pascal E.R. Girin

    9,493,577

    559,510

    8,647,207

    B. Kristine Johnson

    9,912,410

    140,677

    8,647,207

    Matthew B. Klein

    9,971,122

     

    81,965

    8,647,207

    Linda M. Liau

    9,959,656

    93,431

    8,647,207

    Timothy T. Richards

    9,499,321

    553,766

    8,647,207

    2.
    Ratification of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025. The votes were cast as follows:

    For

    Against

    Abstentions

    18,622,225

    5,113

    72,956

    3.
    Advisory approval of executive compensation. The stockholders, on an advisory basis, approved the compensation of the Company’s executives. The votes were cast as follows:

    For

    Against

    Abstentions

    Broker Non-Votes

    9,385,298

    351,323

    316,466

    8,647,207

     


    4.
    Advisory vote to set the frequency of the Company’s future advisory votes on executive compensation. The stockholders, on an advisory basis, approved setting the frequency of future votes on executive compensation at one (1) year. The votes were cast as follows:

    One Year

    Two Years

    Three Years

    Abstentions

    Broker Non-Votes

    9,698,448

    25,410

    58,944

    270,285

    8,647,207

    In light of the above results, on May 22, 2025, the Company’s Board of Directors has elected to include a stockholder vote on the compensation of executives in the proxy materials every year until the next required vote on the frequency of stockholder votes on executive compensation.

    5.
    Approval of the Amended and Restated 2021 Employee Stock Purchase Plan. The stockholders approved the Company’s Amended and Restated 2021 Employee Stock Purchase Plan. The votes were cast as follows:

    For

    Against

    Abstentions

    Broker Non-Votes

    8,721,158

    1,074,535

    257,394

    8,647,207

    6.
    Approval of the Sixth Amended and Restated 2013 Incentive Compensation Plan. The stockholders approved the Company’s Sixth Amended and Restated 2013 Incentive Compensation Plan. The votes were cast as follows:

    For

    Against

    Abstentions

    Broker Non-Votes

    8,440,784

    1,309,359

    302,944

    8,647,207

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

    Description of Exhibit

    10.1

    ClearPoint Neuro, Inc. Sixth Amended and Restated 2013 Incentive Compensation Plan.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    CLEARPOINT NEURO, INC.

     

     

     

     

    Date:

    May 23, 2025

    By:

    /s/ Danilo D'Alessandro

     

     

     

    Danilo D'Alessandro
    Chief Financial Officer

     


    Get the next $CLPT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CLPT

    DatePrice TargetRatingAnalyst
    7/25/2024$10.00Buy
    B. Riley Securities
    10/24/2023$8.00Buy
    Stifel
    2/16/2023$14.00Buy
    B. Riley Securities
    4/5/2022$15.00Buy
    B. Riley Securities
    More analyst ratings

    $CLPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

      B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $10.00

      7/25/24 8:27:37 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on ClearPoint Neuro with a new price target

      Stifel initiated coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $8.00

      10/24/23 6:18:03 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

      B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $14.00

      2/16/23 7:44:43 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

      For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

      11/14/24 8:50:18 AM ET
      $CLPT
      $PTCT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CLPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

      Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This signifies th

      11/13/24 1:20:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Reports Third Quarter 2024 Results

      Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024.Third Quarter HighlightsReported quarterly revenue of $8.1 million, a 41% year-over-year increase;Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase;Overall product revenue, inc

      11/7/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

      President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast TodaySOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE.Healthcare Conferences with Participation of ClearPoint Neuro Management Include:UBS Global Healthcare Conference in

      10/31/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer D'Alessandro Danilo was granted 376 shares, increasing direct ownership by 0.57% to 66,368 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      7/2/25 5:13:49 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Business Officer Stigall L. Jeremy was granted 1,608 shares, increasing direct ownership by 2% to 72,355 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      7/2/25 5:11:30 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Operating Officer Sabra Mazin was granted 361 shares, increasing direct ownership by 0.71% to 51,564 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      7/2/25 5:08:46 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    SEC Filings

    See more
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      6/17/25 4:15:28 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by ClearPoint Neuro Inc.

      144 - ClearPoint Neuro, Inc. (0001285550) (Subject)

      6/3/25 4:13:31 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      5/23/25 4:30:10 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Leadership Updates

    Live Leadership Updates

    See more
    • ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

      SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to have Mazin join our team and bring his valuable and relevant skill set into our organization," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Our pharma and device partners in many ways view ClearP

      9/20/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs

      SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice President of Regulatory Affairs. Ms. McNamara-Cullinane will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to welcome Mary to our team as we fully expect her leadership and experience in Regulatory Affairs will contribute immediately to our partners and to patients globally," commented Joe Burnett, Presiden

      8/8/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

      SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee. Ms. Fallon is the Executive Vice President, HR/Legal, General Counsel and Secretary of Axcelis Technologies, Inc. (NASDAQ:ACLS), a provider of equipment and service solutions for the semiconductor manufacturing industry, with locations in eight countries. Ms. Fallon has held her current position sin

      7/15/21 4:30:00 PM ET
      $CLPT
      $ACLS
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Technology

    $CLPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/12/24 2:35:26 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/8/24 4:33:36 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/4/24 11:28:38 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Financials

    Live finance-specific insights

    See more
    • ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

      SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 third quarter on Thursday, November 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or a

      10/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

      SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 second quarter on Wednesday, August 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or

      7/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

      SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 first quarter on Tuesday, May 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 first quarter on Tuesday, May 7th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201

      4/23/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care